Marksans Pharma Ltd.

30th September, 2020

To,
National Stock Exchange of India Limited
Exchange Plaza
C-1, Block 'G'Bandra Kurla Complex,
Bandra (E), Mumbai – 400051.
Scrip Code: **MARKSANS**

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort,
Mumbai – 400 001.
Scrip Code: **524404**

Sub: Re-appointment of Dr. Meena Rani Surana (DIN: 08863769)

Dear Sirs,

Please be informed that appointment of Dr. Meena Rani Surana (DIN: 08863769) as an additional independent director has come to end on 29th September, 2020. Further, please be informed that the Board of Directors of the Company has today i.e. 30th September, 2020, re-appointed Dr. Meena Rani Surana (DIN: 08863769), subject to approval of the members at the next Annual General Meeting of the Company, as an Additional (Category – Independent) Director of the Company for a term of five (5) consecutive years with effect from 30th September, 2020 not liable to retire by rotation.

Brief profile of Dr. Meena Rani Surana is attached herewith.

Dr. Meena Rani Surana is not related to any Directors of the Company in any manner.

The Company hereby confirms that Dr. Meena Rani Surana is not debarred by SEBI or any other authority.

You are requested to note the above in your records.

Thanking You.
Yours faithfully,

For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary

Brief Profile of Dr. Meena Rani Surana

Dr. Meena Rani Surana is a pharma professional. She is Bachelor of Pharmacy and Ph.D in Pharmaceutics from Indian Institute of Technology, BHU, Varanasi, India and has done a Post Doctoral Fellowship in Pharmaceutics from Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA.

She has about 27 years of experience in pharmaceutical regulatory affairs, quality assurance, formulation and pre-formulation.

She has experience of ANDA filings with US FDA for more than 100 drug products and familiarity with CMC section review of INDs and NDAs of several drug products. She has extensive experience & familiarity with eCTD format & software requirements, SPL Labeling, regulatory requirements of pharmaceutical industry, FDA/ICH/EMEA guidelines, CDER guidelines, Code of Federal Regulations (21 CFR part 314, 201, 210 & 211 etc.), Drug approval process for ANDA/IND/NDA, DMF filing, handling of all drug products post-approval activities, SUPAC guidelines/requirements for IR/MR Drug Products, cGMP/cGLP/Compliance requirements, promotional labeling and marketing requirements, requirements & handling of controlled substances (DEA requirements), Pharmacovigilance requirements for approved & GMP products, etc.

She has also experience, knowledge & involvement in preparation of SOPs, policies & procedures, qualification procedures (equipment, raw materials, contract laboratories, CROs), investigation reports (complaints/OOS/deviations/Incidents etc.) cleaning validation, manufacturing, packaging & warehousing procedures in order to comply GMP requirements at firm, technical reports & protocols, ensuring cGMP training, conducting QA compliance internal audits, ensuring safety regulations etc.

Dr. Meena Rani Surana has published 12 research articles in reputed international journals and presented research work at several conferences. She is reviewer of internationally renowned pharmaceutical journals, including Journal of Pharmacy & Pharmaceutical Sciences (JPPS), AAPS Pharm SciTech and Pharmaceutical Research. She has many awards and honours to her credit.

She is affiliated to American Association of Pharmaceutical Scientists and Indian Pharmaceutical Congress.

Currently, she is practicing as a consultant in the above fields.

MARKSANS PHARMA LTD.